Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Announces Executive Promotions

Business Wire January 27, 2014

European Commission Grants Marketing Authorization for Gilead's Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Business Wire January 17, 2014

U.S. FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin's Lymphoma

Business Wire January 13, 2014

Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13

Business Wire January 10, 2014

Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis

ACCESS Newswire January 7, 2014

Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc

ACCESS Newswire January 7, 2014

Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire

Business Wire January 6, 2014

TrendingWallStreet.com Begins Covering GILD, PFE, SKTO, and CSUN

ACCESS Newswire December 31, 2013

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Business Wire December 18, 2013

Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation

ACCESS Newswire December 17, 2013

Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C

Business Wire December 16, 2013

U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

Business Wire December 13, 2013

Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy

ACCESS Newswire December 10, 2013

Five Star Equities Issues New Research Reports on ACUR, GILD, HOLX and PRAN

ACCESS Newswire December 10, 2013

Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology

ACCESS Newswire December 9, 2013

Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma

Business Wire December 8, 2013

Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia

Business Wire December 7, 2013

U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C

Business Wire December 6, 2013

Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3

Business Wire December 2, 2013

Gilead Sciences, Inc. Uses the PHT Corporation LogPad® System for 1st Antianginal Drug to Treat Type 2 Diabetes

Business Wire December 2, 2013